Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$31.80 – $55.53
40% from low
Exchange
OTC Link
ADRC
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.07B | $2.21B | $2.34B | $2.55B | $2.52B | $2.88B | $3.13B | $3.36B |
| Cost of revenue | $1.02B | $1.06B | $1.14B | $1.25B | $1.28B | $1.47B | $1.71B | $1.91B |
| Gross profit | $1.05B | $1.15B | $1.20B | $1.30B | $1.24B | $1.41B | $1.42B | $1.44B |
| Gross margin | 50.7% | 52.0% | 51.3% | 51.0% | 49.2% | 48.9% | 45.3% | 42.9% |
| R&D | $147.0M | $150.0M | $137.0M | $143.0M | $144.0M | $149.0M | $141.0M | $151.4M |
| Operating income | $371.0M | $493.0M | $579.0M | $582.0M | $282.0M | $367.0M | $612.0M | $569.3M |
| EBITDA | $456.0M | $660.0M | $747.0M | $766.0M | $688.0M | $559.0M | $727.0M | $781.8M |
| Net income | $282.0M | $486.0M | $431.0M | $421.0M | $188.0M | $190.0M | $359.0M | $402.9M |
| Net margin | 13.6% | 22.0% | 18.4% | 16.5% | 7.5% | 6.6% | 11.5% | 12.0% |
| EPS (diluted) | 2.34 | 4.00 | 3.62 | 3.62 | 1.68 | 1.72 | 3.22 | 3.62 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3.5B | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $3.6B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
HIKMA PHARMS PLC S/ADR
No one on the platform currently holds HKMPY.
No tracked institution reports a position in HKMPY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-03-20 | $0.9600 | 2026-05-11 |
| 2025-08-18 | $0.7200 | 2025-09-29 |
| 2025-03-21 | $0.9600 | 2025-05-12 |
| 2024-08-19 | $0.6400 | 2024-09-30 |
| 2024-03-21 | $0.9400 | 2024-05-13 |
| 2023-08-11 | $0.5000 | 2023-09-25 |
No one on the platform has traded HKMPY yet.
| +0.00% |
| $5.8B |
| — |
| LVZPFLivzon Pharmaceutical Group Inc. | $5.22 | +0.00% | $6.1B | — |
| OPHLFOno Pharmaceutical Co., Ltd. | $13.50 | +0.00% | $6.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 12.3× earnings vs its 16.6× historical median P/E.
Fair value ≈ $55.92 · price $41.23 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.